Elbasvir/Grazoprevir + Mycophenolate mofetil = Unknown or no reaction

Effect on Concentration

Elbasvir/Grazoprevir
No change
Applies within class?
No
Mycophenolate mofetil
No change
Applies within class?
No

Pharmacologic Effects

Elbasvir/Grazoprevir
Effect
N/A
Applies within class?
No
Mycophenolate mofetil
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

The authors state that there was no clinically relevant drug interaction between GZR/EBR and MMF.

Sources

Grazoprevir/elbasvir vs tacrolimus, mycophenolate mofetil, prednisone, or cyclosprine ^

Study Design

This was a 4-part, open label, mulitple site study. Each part consisted of 2 periods with a fixed sequence design. In Part 2, the pharmacokinetic (PK) interaction potential between grazoprevir/elbasvir (GZR/EBR) and tacrolimus (TAC) was studied.16 healthy adults were given a single dose of TAC 2mg on Day 1 (Period 1). After a 6-day washout, subjects took GZR/EBR 200/50mg once daily for 16 days, with administration of TAC 2mg on Day 11 in Period 2.

Study Results

Using geometric mean ratios and 90% confidence intervals (GMR, 90% CI), results showed a significant decrease in for GZR AUC andCmaxwhenco-administered with a single dose of MMF.Multiple-dose GZR/EBR had no significant effect on the single-dose PK exposure of MMF.PK ParameterGZR/EBR + MMF / MMFGMR (90% CI)GZR/EBR + MMF / GZRGMR (90% CI)GZR/EBR + MMF / EBRGMR (90% CI)AUC0.95 [0.87, 1.03]0.74 [0.60, 0.92]1.07 [1.00, 1.14]Cmax0.85 [0.67, 1.07]0.58 [0.42, 0.82]1.07 [0.98, 1.16]Cmin0.97 [0.89, 1.06]1.05 [0.97, 1.14]

Study Conclusions

References

Yeh WW, H Feng, L Caro, et al. Clinically meaningful pharmacokinetic interactions between hcv inhibitors grazoprevir/elbasvir with tacrolimus, mycophenolate mofetil, and prednisone, but cyclosprine increases grazoprevir/elbasvir ex. 66th Annual Meeting Of The American Association For The Study Of Liver Diseases (aasld). San Francisco, CA. ; 2015.